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Abstract
Objective: To examine the outcomes of patients with adenoid cystic carcinoma (ACC) treated with post-
operative accelerated hypofractionated radiotherapy (AHRT).
Methods: Patients treated with AHRT (5055 Gy in 20 fractions over 25 days) between 1997 and 2008
were identified and retrospectively analysed. Data collection included site of primary and surgical
excision margin. Primary outcomes were overall survival (OS) and local control (LC) calculated using the
KaplanMeier method.
Results: A total of 37 patients meeting the above criteria were identified with a median age of 55
years (range 3179). Distribution by anatomical site was as follows: parotid 9 patients; submandibular
gland 8 patients; other salivary gland tissue 20 patients. Surgical excision margins were as follows: non-
involved 25 patients; microscopic involvement 7 patients; macroscopic involvement 4 patients; unknown
1 patient. Median follow-up was 59 (range 14126) months. Five patients had local recurrence, 4 distant
recurrences, and 1 both local and distant recurrence. The 5-year LC and OS rates were 81.8% (95%
confidence intervals (CIs) 60.992.2) and 78.5% (95% CI 58.089.8%), respectively.
Conclusion: Outcomes with post-operative AHRT appear comparable to those in the literature. However,
until more is known about the radiobiology of this rare disease, a biological equivalent of 60 Gy in 2 gray
fractions without correction for accelerated repopulation should be used.
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INTRODUCTION
Adenoid cystic carcinoma (ACC) accounts for
approximately 10% of salivary gland tumours.
It is the most common tumour of the minor
salivary glands and is the second most common
tumour of the major salivary glands after
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mucoepidermoid tumours.1 There is a propen-
sity for perineural spread in addition to nodal
and haematogenous spread. The tumours often
have a slow, protracted natural history.
Surgery is well established as the definitive
treatment modality for ACC. Local recurrence
occurs commonly following treatment with
surgery alone. This is thought to occur because
of the infiltrative growth pattern and perineural
spread associated with these tumours, hence
radiotherapy is given post-operatively. The
addition of post-operative radiotherapy has
been shown in several retrospective reviews to
enhance LC rates.17 Radiobiological para-
meters for this tumour have yet to be fully
established, and current treatment schedules
are based upon clinical experience and small
retrospective case series.
Current post-operative schedules used within
the United Kingdom deliver at least 60 Gy in
30 fractions as there is evidence that doses less
than this lead to inferior outcomes.13 Little
data exists regarding the use of accelerated
hypofractionated regimes for ACC. In theory,
this may offer both practical advantages to a
busy radiotherapy department, alongside poten-
tial radiobiological advantages. The present
study determines outcomes following the use
of an accelerated hypofractionated regime in
the post-operative setting for patients with
ACC.
METHODS
All patients treated with accelerated hypofrac-
tionated radiotherapy (AHRT) between 1997
and 2008 were identified and retrospectively
analysed. The dose delivered included 50 Gy,
52.5 Gy or 55 Gy given in 20 fractions over
25 days. Anterior and posterior oblique fields
were used to deliver the treatment with an
anterior matched neck field to treat uninvolved
lymph nodes within levels III to V to a dose of
41.25 Gy in 15 fractions where appropriate.
A retrospective review of hospital notes was
performed. Data collection included site of the
primary tumour and surgical margin status: clas-
sified as clear, microscopically involved or
macroscopically involved.
Primary outcomes were overall survival
(OS) and local control (LC) calculated using
the KaplanMeier method. The time to pro-
gression was defined as the date of starting
radiotherapy until the documented date of fail-
ure for those who relapsed. Patients were cen-
sored at the date of death (if the patient died
from other causes without relapse) or last
follow-up date. Univariate analysis using Cox
proportional hazards models was performed to
assess the influence of the following variable
on outcomes: involvement of resection mar-
gins, age, gender, and site of disease.
RESULTS
Thirty-seven patients were identified and
reviewed. Of these, 13 were male and 24 were
female. The median age at diagnosis was 55
(range 3179) years. Nine patients had parotid
ACC, 8 had submandibular ACC and 20 had
minor salivary gland ACC. Minor salivary gland
tumours included nine tumours within the oral
cavity and the remaining 12 were from other
sites.
Thirty six of the included patients had under-
gone surgical resection of their tumours prior to
receiving radiotherapy. Histology reports were
reviewed, 25 had clear margins, 7 had micro-
scopic involvement of the margins and 4 had
macroscopic involvement. Patient and tumour
characteristics are given in Table 1.
Thirty-one patients were planned conven-
tionally using the simulator. The remaining six
patients, who were the most recent to be trea-
ted, were planned using computerized tomo-
graphy. Table 2 shows the beam arrangements
used. None of the patients were treated with
intensity-modulated radiotherapy.
The median follow-up times for all patients
was 59 (range 14126) months. Ten patients
had developed recurrence: 5 loco-regional, 4
distant recurrences and 1 both loco-regional
and distant recurrence. The median time to
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progression was 21 (range 485) months. The
KaplanMeier plots for LC and OS for all
patients are shown in Figures 1 and 2, respect-
ively. The 5-year LC rate was 81.8% (95% con-
fidence intervals (CIs) 60.992.2).
At the time of analysis, eight patients had died.
Four of these had initially presented with T4 dis-
ease. OS at 5 years was 78.5% (95% CI
58.089.8%). No significant differences in the
rate of LC or OS were found within the cohort
when considering age, gender, T stage or site of
disease. Figure 3 illustrates the survival curves
when considering involvement of the surgical
margin. Involved margins were associated with
reduced OS (p ¼ 0.04). Table 3 compares the
results presented here to those available in the lit-
erature.
DISCUSSION
Radiotherapy is widely accepted as standard
treatment in the post-operative setting for
ACC. Several studies considering a combined
approach of surgery followed by radiotherapy
to a dose of at least 60 Gy (in 2 Gy per fraction
over 39 days) have shown significantly greater
LC than from surgery alone.1,3,7
The reported cohort shows a similar distribu-
tion of sites of ACC as compared to published
data.8,9 Garden et al. reported survival and
disease-free rates for patients with ACC treated
using combined surgery and post-operative
radiotherapy.2 Doses ranged from 5069 Gy
(median, 60 Gy) over 2358 days (median,
42 days). Outcomes were significantly better
in those who received a post-operative radiation
dose of 60 Gy or more. The 5-year LC rate,
freedom from relapse rate and OS were 95%,
68% and 82%, respectively.
The accelerated hypofractionated regime
reported here appears to be associated with sim-
ilar LC and OS to conventional radiation sche-
dules. At present, the radiobiology of ACC is
poorly understood. Both the a/b ratio and sig-
nificance of accelerated repopulation for ACC
remain unknown. AHRT has been used suc-
cessfully in squamous cell carcinoma of the
head and neck cancer largely due to the shor-
tened overall treatment time counteracting
accelerated repopulation.10 In prostate cancer,
hypofractionated radiotherapy has also been
used successfully but in this disease due to the
postulated low a/b ratio.11,12
The small number of patients within this
study limits conclusions with respect to variables
analysed. However, consistent with other series,
involvement of surgical margins was associated
with a worse OS. With the exception of
increasing T stage, other studies have failed to
consistently identify any other significant pro-
gnostic factors.4,6,8,13
Table 1. Patient characteristics
Patient characteristics n Percentage
Total entered 37
Gender
Male 13 35.1%
Female 24 64.9%
Age (years)
Median (interquartile range) 55 (4564)
Range 3179
Site
Parotid gland 9 24.3%
Submandibular gland 8 21.6%
Minor salivary glands 20 54.1%
T stage
T1 4 10.8%
T2 14 37.8%
T3 7 18.9%
T4 7 18.9%
Unknown 5 13.6%
N stage
N0 29 78.4%
N1 6 16.2%
N2 2 5.4%
Surgical excision
Yes 36 97.3%
No 1 2.7%
Table 2. Radiotherapy technique
Beam arrangement n Percentage
Wedge pair 27 73.0
Parallel opposed 4 10.8
3 Field (anterior and 2 laterals) 5 13.5
Unknown 1 2.7
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Figure 1. KaplanMeier plot of local control.
Figure 3. Overall survival by involvement of surgical margins.
Figure 2. KaplanMeier plot of overall survival rates.
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Other series used post-operative radiation
doses ranging from 50 to 79.89 Gy, given in
2 Gy fractions (Table 3). Chen et al. reported
90 patients who received post-operative radio-
therapy to a mean dose of 64 Gy, with a median
follow-up of 66 months. Compared to our
cohort, a greater proportion of patients had
T3 (20%) and T4 (26%) disease and involved
surgical margins (63%), yet a superior 5-year
LC rate of 92% was achieved.1 Furthermore,
the series by Gomez et al. (mean dose 63 Gy)
also contained a higher proportion of patients
with T3 (14%) and T4 (34%) disease and a 5-
year LC of 91% was reported.4 Both these stud-
ies support the use of 2 Gy fractionation over
accelerated hypofractionation. However, Iseli
et al. reported 87 patients (median dose
62 Gy) and the 5-year LC rate was 73.4%.
This cohort included 44.4% T3 or T4 disease.14
Mendenhall et al. reported 5-year LC of 94% in
a cohort of 59 patients treated with either pre- or
post-operative radiotherapy with varying dose-
fractionation schedules: pre-operative RT, 50
Gy (range, 45 Gy61.3 Gy); and post-operative
RT, 67.8 Gy (range, 10.5 Gy76.8 Gy), in
either 2 Gy per fraction or a hyperfractionated
regime treating twice daily.6 It is difficult to
compare this series with ours in view of the het-
erogeneity of the dose-fractionation schedules.
The possibility that AHRT over 4 weeks is
associated with inferior outcome cannot be
excluded. To achieve radiobiological equival-
ence with a 60 Gy in 30-fraction regime, there
would need to be a significant degree of accel-
erated repopulation to realise any benefit from
the shortened schedule. Alternatively, in the
complete absence of accelerated repopulation,
an a/b ratio of 0.5 Gy would be required to
give equivalence to 60 Gy in 30 fractions
(see Appendix 1 for calculation). It is possible
that a combination of moderate accelerated
repopulation and a slightly decreased a/b ratio
would also render the schedules equivalent.
Multicentre prospective randomised trials are
unlikely to be performed given the rarity of
this disease and its long natural history. There-
fore caution should be exercised when using
altered fractionation for this disease. Following
completion of this study, the local institutional
policy for ACC has been revised. In the pres-
ence of involved margins, a dose of 65 Gy
in 30 fractions over 39 days is administered.
In the absence of margin involvement, a
Table 3. Comparison of the results from this study with those from the literature
Study Number of patients RT dose/fractionation 5-Year local control rate 5-Year overall survival
This study 38 5055 Gy/20
fractions
81.8% 95%
CI: (60.9, 92.2)
78.5% 95%
CI: (58.0, 89.8)
Chen et al.1 90 64 Gy (range 5471 Gy)/32
fractions
92% Not reported
Garden et al.2 198 60 Gy (range 5069 Gy)/30
fractions
95% Not reported
Gomez et al.4 59 63 Gy (range 5270 Gy)/32
fractions
91% 87%
Khan et al.8 41 57.3 Gy Not reported 72%
Iseli et al.14 87 62 Gy (range 1572 Gy)/31
fractions
73.4% 75.5%
Gurney et al.5 33 50.479.89 Gy 94% 85%
Mendenhall
et al.6
59 5072 Gy (in 2 Gy fractions
either daily or twice daily in
a hyperfractionated regime)
94% 77%
Silverman
et al.13
50 59.8 Gy (range 4572 Gy
in 1.82 Gy fractions)
84.5% 79.8%
Chunying
et al.7
28 58 Gy (range 5060 Gy) 89.8% Not reported
CI, confidence interval; RT, radiotherapy.
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dose of 60 Gy in 30 fractions over 39 days is
administered.
It is possible that AHRT in the post-operat-
ive setting for ACC leads to an inferior out-
come and we recommend using 2 Gy
fractionation to a minimum dose of 60 Gy.
APPENDIX
To determine a/b of ACC if AHRT is equi-
valent to conventional fractionation in the
absence of accelerated repopulation associated
with ACC, the following equation is solved:
BED (biologically effective dose) hypofrac-
tionated regime without time correction ¼
BED conventional regime
Dh
1þ dh
a=b
 
¼ Dc 1þ dc
a=b
 
where Dh ¼ total dose hypofractionated
regime ¼ 50 Gy; dh ¼ dose per fraction hypo-
fractionated regime ¼ 2.5 Gy; a/b ¼
unknown; Dc ¼ total dose conventional
regime ¼ 60 Gy; dc ¼ 2 Gy
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